From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structuralprotein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .
ML303 is a pyrazolopyridine influenza virus nonstructuralprotein 1 (NS1) antagonist (IC90 = 155 nM), with an EC50 of 0.7 μM for Influenza A virus H1N1 .
Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structuralprotein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .
Yimitasvir (Emitasvir) is an orally active hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor. Yimitasvir can be used for research of chronic HCV infection .
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .
KK4A peptide is a small peptide derived from nonstructuralprotein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
Coblopasvir (KW-136) is a pangenotypic non-structuralprotein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .
Elbasvir (MK-8742) is a hepatitis C virus nonstructuralprotein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructuralprotein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2non-structuralprotein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2non-structuralprotein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructuralprotein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructuralprotein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structuralprotein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructuralprotein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM .
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructuralprotein (NS), served as the substrate for the study of HCV NS3 protease activity .
SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structuralprotein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructuralprotein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates .
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructuralprotein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC90 ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model .
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structuralprotein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
GS-9851 (PSI-7851) is an HCV nonstructuralprotein 5B (NS5B) inhibitor with potential activity for the treatment of HCV infection. GS-9851 showed good tolerability in patients with initial HCV genotype 1 infection. GS-9851 is rapidly cleared from the body with a half-life of approximately 1 hour. The maximum concentration of GS-9851 and the increase in the area under the compound concentration-time curve were not dose-proportional, especially at the highest dose .
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structuralprotein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structuralprotein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .
DBPR110 is a nonstructuralprotein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .
KK4A peptide is a small peptide derived from nonstructuralprotein 4A (NS4A) of hepatitis C virus (HCV) that significantly increases the catalytic efficiency of NS3 protease. The KK4A peptide may be used to gain insights into the function and mechanism of the HCV NS3 protease, thereby advancing research into HCV infection .
NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructuralprotein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of CD8 + cytotoxic T lymphocyte (CTL) in antiviral immune responses .
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructuralprotein (NS), served as the substrate for the study of HCV NS3 protease activity .
Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu-ψ-(COO)Ala-Ser-Lys(DABCYL)-NH2 (HCV NS3 protease substrate) is a biological active peptide. (This peptide is a HCV protease substrate incorporating an ester bond between residues P1 and P1. Due to ready transesterification of the scissile bond to the acyl-enzyme intermediate, this substrate shows very high kcat/Km values, enabling detection of activity with subnanomolar nonstructuralprotein 3 (NS3 protease) concentrations. It is widely used for the continuous assay of NS3 protease activity. Substrate cleavage is proportional to the enzyme concentration with a detection limit for NS3 between 1 nM and 250 pM. Upon cleavage of this substrate, fluorescence can be monitored at Abs/Em = 355/500 nm.)
Nonstructural protein 1/NS1 plays multiple roles in viral infection.It inhibits cellular pre-mRNA processing by binding to CPSF4 and PABPN1, disrupting normal 3' end processing and halting host protein synthesis.Non-structural protein 1/NS1 Protein, H1N1 (His) is the recombinant Virus-derived Non-structural protein 1/NS1 protein, expressed by E.coli , with N-His labeled tag.
NS5 Protein is part of the flavivirus RNA replication complex (RC) composed of viral non-structural proteins and host-cell cofactors. NS5 is the largest flavivirus protein, the most conserved, which act as two domains, the RNA-dependent RNA polymerase (RdRp) and RNA methyltransferase enzyme (MTase). NS5 plays a fundamental role in flavivirus replication, viral RNA methylation, RNA polymerization, and host immune system evasion. NS5 Protein, Dengue virus 2 (His) is the recombinant Virus-derived NS5 protein, expressed by E. coli , with N-His labeled tag. The total length of NS5 Protein, Dengue virus 2 (His) is 296 a.a., with molecular weight of ~35.5 kDa.
Nonstructural protein 2/NS2 protein plays a crucial role in the influenza virus life cycle by mediating the nuclear export of capsid genomic RNA and is the link between the viral ribonucleoprotein complex (RNP) and the host cell nuclear export machinery. Important ties. Non-structural protein 2/NS2 Protein, H1N1 (His) is the recombinant Virus-derived Non-structural protein 2/NS2 protein, expressed by E. coli , with N-His labeled tag. The total length of Non-structural protein 2/NS2 Protein, H1N1 (His) is 121 a.a., with molecular weight of ~13 KDa.
Growth factor-like peptide; Leader protein; Non-structural protein 10; Non-structural protein 2; Non-structural protein 3; Non-structural protein 4; Non-structural protein 6; Non-structural protein 7; Non-structural protein 8; Non-structural protein 9; Papain-like proteinase; p65 homolog
Replicase 1AB polyprotein Protein, SARS-CoV (Cell-Free, His) is the recombinant Virus-derived Replicase 1AB polyprotein protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of Replicase 1AB polyprotein Protein, SARS-CoV (Cell-Free, His) is 290 a.a., with molecular weight of 35.8 kDa.
SARS-CoV-2 NSP9 Protein (His-Avi) is the recombinant Virus-derived SARS-CoV-2 NSP9 protein, expressed by E. coli , with C-Avi, N-His labeled tag. The total length of SARS-CoV-2 NSP9 Protein (His-Avi) is 113 a.a., with molecular weight of ~15.5 kDa.
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructuralprotein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
Inquiry Online
Your information is safe with us. * Required Fields.
